{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T09:47:12Z","timestamp":1776505632996,"version":"3.51.2"},"reference-count":67,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T00:00:00Z","timestamp":1333584000000},"content-version":"vor","delay-in-days":766,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p>Proton pump inhibitors (PPIs) have been recommended for reducing the risk of gastrointestinal bleeding associated with dual antiplatelet therapy (aspirin plus clopidogrel). However, studies have found decreased efficacy of clopidogrel when concurrently administered with a PPI. To determine the mechanism of and evidence for the potential interaction between clopidogrel and PPIs, along with the clinical implications of this drug interaction, we reviewed recently published reports of trials that examined the interaction. A MEDLINE database search (1966\u2010September 2009) for English\u2010language reports of clinical trials in human subjects was performed, supplemented by a manual search of reference lists. Four trials that examined surrogate outcomes and eight trials that examined clinical outcomes were included in this review. Two surrogate outcome studies showed that PPIs negatively affected clopidogrel response and increased platelet aggregation, whereas the other two did not find a significant difference between groups receiving PPIs and not receiving PPIs. Three of four published clinical outcomes studies and three of four unpublished clinical outcomes studies available as abstracts found a significant association between PPI use and rates of acute myocardial infarction, rehospitalization, death, or stroke. Most of the currently available data, primarily from observational studies, show that some PPIs may decrease clopidogrel's antiplatelet effectiveness, with increased cardiac adverse outcomes when clopidogrel is combined with PPIs. Although current data do not show causation of adverse outcomes with PPI use because the available data are conflicting, this topic is still controversial. Careful risk\u2010benefit assessment is required before prescribing PPIs for individual patients taking dual antiplatelet therapy. More evidence from randomized controlled trials is needed to clarify this drug interaction dilemma.<\/jats:p>","DOI":"10.1592\/phco.30.3.275","type":"journal-article","created":{"date-parts":[[2010,2,24]],"date-time":"2010-02-24T13:11:19Z","timestamp":1267017079000},"page":"275-289","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Drug Interaction Between Clopidogrel and Proton Pump Inhibitors"],"prefix":"10.1002","volume":"30","author":[{"given":"Tina J.","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia A.","family":"Jackevicius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,5]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2411"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.09.011"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/HPC.0b013e318159921e"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191087"},{"key":"e_1_2_1_7_2","volume-title":"Plavix (clopidogrel) package insert","author":"Bristol\u2010Myers Squibb\u2010sanofi\u2010aventis.","year":"2008"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2007.03.012"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.crd.0000188033.11188.8e"},{"key":"e_1_2_1_10_2","first-page":"33","article-title":"Clopidogrel: some drugs may reduce its effectiveness [drug interactions]","volume":"4","author":"Horn JR","year":"2000","journal-title":"Pharm Times"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629090-00002"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00788.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000112378.09325.F9"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.12.044"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.04.045"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2008.00936.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2008.05.001"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2003.10.013"},{"key":"e_1_2_1_20_2","first-page":"921","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"108","author":"Gurbel PA","year":"2003","journal-title":"Circulation"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613462"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629090-00002"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00788.x"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.8.821"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.06.064"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008315310"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.09.017"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-12-0808"},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton pump inhibitor: an analysis of two randomized trials","volume":"374","author":"O'Donoghue ML","year":"2009","journal-title":"Lancet"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.05.053"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.082001"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.261"},{"key":"e_1_2_1_33_2","first-page":"S815","article-title":"Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel Medco outcomes study [abstract 3998]","volume":"118","author":"Auber RE","year":"2008","journal-title":"Circulation"},{"key":"e_1_2_1_34_2","first-page":"S815","article-title":"Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial [abstract 3999]","volume":"118","author":"Dunn SP","year":"2008","journal-title":"Circulation"},{"key":"e_1_2_1_35_2","unstructured":"StanekEJ AubertRE FlockhartFA et al.A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the clopidogrel Medco outcomes study. Presented at the meeting of the society of cardiovascular angiography and interventions Las Vegas Nevada May 69 2009."},{"key":"e_1_2_1_36_2","unstructured":"BhattDL CryerB ContantCF et al.Clopidogrel and the optimization of GI events trial (COGENT). Presented at the transcatheter cardiovascular therapeutics meeting San Francisco California September 2125 2009."},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.10497"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2007.03.022"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A0917"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.051"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.10.2904"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0670"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.01062.x"},{"key":"e_1_2_1_44_2","first-page":"693","article-title":"Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous intervention: a case control study","volume":"38","author":"Chin MW","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.111150798"},{"key":"e_1_2_1_46_2","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/bmj.38947.697558.AE","article-title":"Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case\u2010control study [online exclusive article]","volume":"333","author":"Hallas J","year":"2006","journal-title":"BMJ"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042087"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-5-359"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-4-257"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-9-735"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410140047006"},{"key":"e_1_2_1_52_2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archinte.1989.00390050025005","article-title":"The relative gastrointestinal toxicity of nonsteroidal anti\u2010inflammatory drugs","volume":"149","author":"Carson JL","year":"1989","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90118-H"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-4-199508150-00001"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02687.x"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K227"},{"key":"e_1_2_1_57_2","unstructured":"U.S. Food and Drug Administration.Bulletin: early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix) January 2009. Available fromhttp:www.fda.govcderdrugearly_commclopidogrel_bisulfate.htm. Accessed April 21 2009."},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00021.x"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000298158.12101.41"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.08.045"},{"key":"e_1_2_1_61_2","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1001\/archinte.1996.00440190069008","article-title":"Prevention of nonsteroidal anti\u2010inflammatory drug\u2010induced gastrointestinal mucosal injury","volume":"156","author":"Koch M","year":"1996","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605303342204"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199412000-00013"},{"key":"e_1_2_1_64_2","unstructured":"TheHeart.org by WebMD.COGENT\u20101 trial scrapped sponsor declares bankruptcy January 2009. Available fromhttp:www.theheart.orgarticle936651.do. Accessed March 9 2009."},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808227"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.03.073"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.09.013"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.30.3.275","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.30.3.275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:03:45Z","timestamp":1761048225000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.30.3.275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1592\/phco.30.3.275"],"URL":"https:\/\/doi.org\/10.1592\/phco.30.3.275","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"2012-04-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}